Physician profile
Maged Elkhouly
NPI 1619254174
$25,102.48
in general payments reported to CMS, 2019-2025
9 companies · $6,241 in 2025
The $6,241 reported for 2025 was more than what 92% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.89 · 2022: $16K · 2023: $3,122 · 2024: $38.08 · 2025: $6,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $9,000 · Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $9,000.00 |
| Food and Beverage | $401.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $24,876.24 | 2022-2025 | Davinci Xi, Da Vinci Surgical System |
| Regeneron Healthcare Solutions, INC. | $47.09 | 2024-2025 | Dupixent |
| Medtronic, INC. | $41.47 | 2025 | Progrip |
| Mallinckrodt Hospital Products INC. | $28.33 | 2023 | Terlivaz |
| Ethicon US, LLC | $25.11 | 2023 | Echelon; Endopath |
| Braintree Laboratories, INC. | $24.89 | 2019 | |
| Kerecis Limited | $23.47 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Convatec INC. | $20.94 | 2023 | |
| Celgene Corporation | $14.94 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maged Elkhouly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.